Down the Critical Path: Who Should Lead?
In: Applied Clinical Trials, Jg. 14 (2005-08-01), Heft 8, S. 56-56
academicJournal
Zugriff:
Reports that U.S. Food and Drug Administration issued a proactive white paper that deals with innovation and stagnation on the development of new medical products. Factor causing the increased in clinical costs; Sources of variability in human response; Demonstration of the medical utility.
Titel: |
Down the Critical Path: Who Should Lead?
|
---|---|
Autor/in / Beteiligte Person: | Milne, Christopher-Paul ; Kaitin, Kenneth I. |
Zeitschrift: | Applied Clinical Trials, Jg. 14 (2005-08-01), Heft 8, S. 56-56 |
Veröffentlichung: | 2005 |
Medientyp: | academicJournal |
ISSN: | 1064-8542 (print) |
Schlagwort: |
|
Sonstiges: |
|